Reports Q3 revenue $61.2M, consensus $62.27M. David Bailey, President & CEO of OrthoPediatrics (KIDS), commented “We are proud of the company’s overall third quarter performance. Although, 7D and Latin and South America did not meet our expectations, OrthoPediatrics continues to lead the pediatric orthopedic market by delivering comprehensive solutions that advance the care of children worldwide. Our focus remains on strong execution of our strategic initiatives including scaling OPSB, leveraging prior set deployments, and introducing innovative new products. We are confident this approach will drive revenue growth, increase adjusted EBITDA, and meaningfully reduce cash burn as we move toward achieving free cash flow break-even in 2026. Ultimately, we believe our strategy positions OrthoPediatrics to help more children than ever before.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KIDS:
- KIDS Upcoming Earnings Report: What to Expect?
- OrthoPediatrics price target lowered to $34 from $37 at Lake Street
- OrthoPediatrics price target lowered to $18 from $22 at Truist
- OrthoPediatrics price target lowered to $23 from $39 at BTIG
- OrthoPediatrics price target lowered to $25 from $35 at Citizens JMP